Abstract 17P
Background
Ovarian cancer is the most lethal gynecological malignancy worldwide and is known to have a poor prognosis among gynecological cancers. Recently, PD-1/PD-L1 inhibitors have demonstrated promising clinical outcomes in the treatment of OC. However, only about 20% of patients respond to these therapies, highlighting the need for improved patient selection. LncRNAs are significantly involved in tumor proliferation, apoptosis, migration, and metastasis and have significant associations with immune cell infiltration and the cancer cell response to anti-PD-1 immunotherapy in various tumors. Based on reports that immune-related lncRNAs play a role in regulating the PD-1/PD-L1 mechanism, this study aims to identify predictive biomarkers for ovarian cancer.
Methods
We analyzed the mRNA and protein levels of PD-L1 in OC patient tissues and classified them into high and low PD-L1 expression groups. We performed lncRNA microarray analysis on the classified groups. As a result, we identified MIR4435-2HG as lncRNA associated with PD-L1 overexpression. Furthermore, MIR4435-2HG knockdown were conducted. Other features, including cell growth, apoptosis, migration and invasion were also analyzed.
Results
A positive correlation between PD-L1 and MIR4435-2HG was observed in both OC tissues and cell lines. Knockdown of MIR4435-2HG in OC cell lines resulted in decreased PD-L1 expression and induce cellular apoptosis and inhibit cell migration and invasion. Moreover, GO analysis revealed that MIR4435-2HG is associated to immune-related genes.
Conclusions
Therefore, this study suggests that the lncRNA MIR4435-2HG associated with PD-L1 may be used as a predictive biomarker and therapeutic target in ovarian cancer.
Legal entity responsible for the study
The Catholic University of Korea, Industry-Academic Cooperation Foundation.
Funding
The National Research Foundation of Korea (NRF).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract